CVRx vs Pulmonx
CVRX and LUNG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVRX and LUNG compare
Pulmonx is the larger company, worth 7.6 times as much as CVRx ($123M against $16.2M).
CVRx grew revenue faster over the last twelve months (7.8% versus −3.2% for Pulmonx).
Pulmonx keeps more of each dollar of sales as profit, with a net margin of −47.9% compared with −88.3% at CVRx.
Pulmonx scores higher on the StockData Score (6 against 5 for CVRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVRX | LUNG |
|---|---|---|
| Size and price | ||
| Market cap | $16.2M | $123M |
| Share price | $0.607 | $2.86 |
| Change, 1 year | −93.6% | 45.9% |
| Change, 5 years | −95.4% | −91.7% |
| Beta (5Y) | 1.14 | 1.73 |
| Employees | 223 | 296 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 1.4× |
| P/B | 1.2× (better) | 3.6× |
| FCF yield | −260% | −20.8% (better) |
| Fair value | – | $4.74 |
| Margin of safety | – | 39.7% |
| Growth | ||
| Revenue growth (TTM) | 7.8% (better) | −3.2% |
| Revenue growth, 5Y average | 56.4% (better) | 22.6% |
| Profitability | ||
| Gross margin | 86.9% (better) | 77.4% |
| Operating margin | −81.9% | −44.4% (better) |
| Net margin | −88.3% | −47.9% (better) |
| FCF margin | −69.7% | −28.8% (better) |
| Return on equity | −172% | −90.3% (better) |
| Return on invested capital | −299% | −156% (better) |
| Financial health | ||
| Debt / equity | 4.24 | 1.11 (better) |
| Interest coverage | −8.0× (better) | −9.4× |
| Current ratio | 6.80 (better) | 4.05 |
| Altman Z-score | −10.15 | −5.75 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −35.1% | – |
| Shareholder yield | −35.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 57.4% | 61.0% |
| Held by insiders | 49.9% | 16.6% |
| Insider net buying, 12 months | $247K (better) | −$548K |
| Short interest, % of float | 13.6% | 2.2% |
Go deeper
- CVRX stock overview
- CVRX income statement
- CVRX valuation and score
- LUNG stock overview
- LUNG income statement
- LUNG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.